Hormonal
GLP-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk, primarily by reducing non-fatal myocardial infarction and stroke.
If you have Type 2 Diabetes and are at high risk for heart disease, GLP-1 receptor agonists (like semaglutide or liraglutide) are a primary treatment option that not only lowers blood sugar but significantly reduces the risk of heart attack and stroke. These medications are taken via injection (daily or weekly) and have been shown in large clinical trials to improve cardiovascular outcomes compared to placebo.
GLP-1 RAs appear to modify atherosclerotic and ischemic endpoints, such as stroke and myocardial infarction (MI)... GLP-1 RAs offer demonstrable cardiovascular protection with 12%–26% reductions in major adverse cardiovascular events (MACE)... driven by reductions in ischemic events, although emerging evidence also supports benefits in other cardiovascular conditions, such as heart failure with preserved ejection fraction.
Why this rating
The claim is supported by multiple large-scale Phase 3 clinical trials (REWIND, LEADER, SUSTAIN 6, PIONEER 6) and meta-analyses involving tens of thousands of participants.
Source
Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future
James P. Psaltis et al. · Medicinal Research Reviews · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →